CHENGDU, China, June 28 /PRNewswire-Asia-FirstCall/ —
Tianyin Pharmaceutical (NYSE Amex: TPI), a biopharmaceutical company that specializes
in patented biopharmaceutical, modernized traditional Chinese
medicine and branded generics will exhibit and promote its flagship
product portfolio at the 45th 2010 National New Special Drugs Trade
Fair at Beijing National Convention Center from July 8th, till July
10th. Tianyin’s portfolio is featured by the patented Ginkgo
Mihuan Oral Liquid (GMOL) for cardiovascular and central nervous
system indications, Apu Shuangxin (APU, Benorylate Granules) for
fever, inflammation and rheumatism, Xuelian Chongcao Oral Solution
(XLCC) for heart diseases, asthma and gynecological conditions,
along with other prescription medicines that target high incidence
China health care indications.
“Years of sales and marketing efforts by Tianyin Pharmaceutical
have established a nationwide network that covers more than 850
hospitals with an in-depth market penetration,” said Dr. Jiang,
Guoqing. “The network synergizes with our marketing strategies that
target high incidence, chronic conditions in a growing aging
Chinese population whose health care spending is boosted by an
increasing disposable income and health care funding by the
government. This synergy is centered on our flagship portfolio such
as GMOL, APU, and XLCC etc. that contributes close to 50% of our
annual revenue.”
About National New Special Drugs Trade Fair
SOURCE
